BioInfra Co., Ltd.
Research BioInfra Co., Ltd. (199730.KQ) on Bullrun: market cap KRW 12.53B, dividend yield 11.7%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker199730.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 12.53B
- Dividend yield11.7%
- Financial periodQ2 2026
- RevenueKRW 8.50B
- Net incomeKRW 1.51M
- Free cash flowKRW 440.34M
- Gross margin30.7%
Valuation Snapshot
latest market cap is KRW 12.53B; dividend yield is 11.7%.
Peer valuation comparison
Latest dividend yield is 11.65% versus a Healthcare sector median of 2.4% (385.4% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 12.53B | n/a | 11.7% | 300 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 300 KRW, yield 11.7%.
About BioInfra Co., Ltd.
BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioInfra Co., Ltd.'s market cap?
BioInfra Co., Ltd.'s market capitalization is KRW 12.53B.
Does BioInfra Co., Ltd. pay a dividend?
BioInfra Co., Ltd. has a dividend yield of 11.7%.
What does BioInfra Co., Ltd. do?
BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing.